Safety of Endobronchial Mesenchymal Stromal Cells in the Treatment of Chronic Lung Allograft Dysfunction

NCT06514378

Status	RECRUITING
Phase	Phase 1
Sponsor	Instituto De Investigación Sanitaria Puerta De Hierro-Segovia De Arana
Enrollment	12 participants

Key Eligibility Criteria

Inclusion (1)

• Patients should have signed written informed consent. Adult patients e18 years of age at the time of enrolment Patients recipients of a uni or bipulmonary transplant An established diagnosis of BOS g 0p (FEV1d90% and / or FEF 25-75% d of the baseline value with no other justifying cause) in the last 6 months.

Exclusion (1)

• History of lobar transplantation History of heart-lung transplantation Active infection at the time of inclusion. Active Acute Rejection not treated at the time of inclusion. Oncological history (except cutaneous basal cell or carcinoma in situ) Systemic autoimmune diseases. Active HIV / HBV / HCV infection (confirmed by serology or PCR) Proximal airway stenosis Pregnancy Performance status 3 or 4 (confined to bed or chair for more than 50% of waking hours, able only to perform some self-care activities) Estimated survival less than 3 months. Known hypersensitivity to components used in the production of allogeneic MSCs. Any circumstance that, in the opinion of the investigator, compromises the patient's ability to participate in the clinical trial.

Locations (1 total)

Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain